ClinicalTrials.gg

Gastroenteritis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 237 studies for Gastroenteritis across more than 10 countries. 16 are recruiting or about to start. 134 of them are mainly about Gastroenteritis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-03. Counting its 25 narrower conditions too, such as Crohn Disease: 6,070 studies, 1,307 open.

Status

Completed
170
Status unknown
21
Terminated
16
Recruiting
13
Withdrawn
8
Active, not recruiting
5

Phase

Phase 3
63
Phase 2
34
Phase 4
23
Phase 1
23
Early Phase 1
1

Where

United States
58
Canada
24
France
14
India
12
Netherlands
11
Italy
10

Who develops what

Add Gastroenteritis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 1 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Bausch Health Companies and Sinovac Biotech here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
MetoclopramideRecent, limited
Evidence
  • NCT05876585 · genuine research center egypt · Phase 3 · live · comparator · “Metoclopramide 10 mg ampoule” · registered Mar 2023
Evoke Pharma50% of its industry studiesUS: off-patent, 12 generics marketed11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 20 Apr 2027 est.Rifaximin · Bausch Health Companies Inc. · Phase 4 named, not the main aimNCT07285785 Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea — primary endpoint: Peak Plasma Concentration (Cmax) of Rifaximin · 54 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Gastroenteritis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antiemetics 1 open · Corticosteroids 1 open

Coming up

7studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 7, phase 3 first

Who these studies take

Of the 13 Gastroenteritis studies recruiting now, 5 (38%) set no upper age limit and 8 (62%) stop at 75 or younger. 11 (85%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (23%) take healthy volunteers.

Recruiting studies that take each age, of 13
AgeWomenMen
106 (46%)6 (46%)
187 (54%)7 (54%)
305 (38%)5 (38%)
405 (38%)5 (38%)
505 (38%)5 (38%)
655 (38%)5 (38%)
755 (38%)5 (38%)
855 (38%)5 (38%)

Across all 237 studies, recruiting or not: 80% stop at 75 or younger and 78% at 65; 77% take children; 0% are for women only and 3% for men only; 41% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Gastroenteritis studies take

Of 25 phase 3 interventional studies under Gastroenteritis, half reached primary completion within 19 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 319 mo11–36 · 25 studies18 mo10–34 · 21 studies—
Interventional, no phase11 mo4–22 · 17 studies——
Observational43 mo30–161 · 17 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 237. Browse all 237 → or search them.